Researchers in China have conducted the first human trial of a chemogenetic therapy aimed at controlling epilepsy. The experimental treatment, which uses genetically modified cells to respond to a specific drug, successfully reduced seizure frequency by 92.6% in participants with refractory epilepsy. This novel approach offers a potential alternative for patients who do not respond to conventional medications or surgical interventions. AI
RANK_REASON Novel medical research with human trial results. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →